Downloads: 124 | Views: 430 | Weekly Hits: ⮙1 | Monthly Hits: ⮙1
Research Paper | Pharmaceutical Science | India | Volume 9 Issue 2, February 2020 | Rating: 6.3 / 10
Ebola
Anshupa Patel Gupta [2] | Himani Tambde [3]
Abstract: Ebola virus disease or simply Ebola is lethal viral hemorrhagic fever caused by Ebola viruses. Many outbreaks have been seen from 1976 to recent 2016, killing around 50 % of persons affected. The Ebola virus includes six species of virus out of which Zaire ebolavirus has highest mortality rate. To get protection against this virus, the vaccine was invented by scientists at the Public Health Agency of Canada (PHAC). In 2014, Merck got the licence to develop this from Newlink (which was first licensed from PHAC). Now Merck Sharp & Dohme Corp has got approval in December 2019 for manufacturing it under the trade name ERVEBO®. ERVEBO is a live recombinant viral vaccine in the form of sterile suspension for intramuscular injection. It is to be administered in single 1 ml dose. Though it has few adverse effects it will certainly be a milestone fighting against Ebola disease.
Keywords: Ebola virus, Ebola virus disease EVD, vaccine
Edition: Volume 9 Issue 2, February 2020,
Pages: 1858 - 1860